Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Saved in:
| Title: | Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. |
|---|---|
| Authors: | Spiera R; Weill Cornell Medical College, New York, New York., Kuwana M; Nippon Medical School Graduate School of Medicine, Tokyo, Japan., Khanna D; University of Michigan, Ann Arbor., Hummers L; John Hopkins University School of Medicine, Baltimore, Maryland., Frech TM; University of Utah and Salt Lake City VA Health Care System, Salt Lake City, Utah., Stevens W; St. Vincent's Hospital, Melbourne, Victoria, Australia., Matucci-Cerinic M; Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology AOUC, Florence, and Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy., Kafaja S; David Geffen School of Medicine at University of California, Los Angeles (UCLA)., Distler O; University Hospital Zurich, University of Zurich, Zurich, Switzerland., Jun JB; Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea., Levy Y; Meir Medical Center, Kfar Saba, Israel., Leszcyzński P; Medyczne Centrum Hetmanska, Poznan, Poland., Gordon J; Weill Cornell Medical College, New York, New York., Steen V; Georgetown University School of Medicine, Washington, DC., Lee EB; Seoul National University College of Medicine, Seoul, South Korea., Jankowski T; Klinika Reumatologii Ukladowych Chorob Tkanki Lacznej Szpital Uniwersytecki, Bydgozzcz, Poland., Litinsky I; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Chung L; Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, California., Hsu V; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey., Mayes M; McGovern Medical School, The University of Texas Health Science Center at Houston., Sandorfi N; Perelman School of Medicine at the University of Pennsylvania, Philadelphia., Simms RW; Boston University School of Medicine, Boston, Massachusetts., Finzel S; Department of Rheumatology and Clinical Immunology, University Medical Center, Universitätsklinikum Freiburg, Freiburg, Germany., de Vries-Bouwstra J; Leiden University Medical Center, Leiden, The Netherlands., Constantine S; Corbus Pharmaceuticals, Inc., Norwood, Massachusetts., Dgetluck N; Corbus Pharmaceuticals, Inc., Norwood, Massachusetts., Dinh Q; Corbus Pharmaceuticals, Inc., Norwood, Massachusetts., Bloom BJ; Corbus Pharmaceuticals, Inc., Norwood, Massachusetts., Furst DE; Department of Experimental and Clinical Medicine, University of Florence, and Division of Rheumatology AOUC, Florence, Italy, David Geffen School of Medicine at UCLA, Los Angeles, California, and University of Washington, Seattle, UK., White B; Corbus Pharmaceuticals, Inc., Norwood, Massachusetts., Denton CP; UCL Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK. |
| Corporate Authors: | RESOLVE-1 Study Group |
| Source: | Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2023 Sep; Vol. 75 (9), pp. 1608-1618. Date of Electronic Publication: 2023 Jun 15. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2326-5205 |
|---|---|
| DOI: | 10.1002/art.42510 |
